Skip to content
Peptide research

Pemvidutide

Also known as ALT-801
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A dual GLP-1/glucagon receptor agonist (1:1 ratio) for weight loss and fatty liver disease (MASH/MASLD). The human evidence is unusually solid: trials show substantial liver fat reduction and meaningful weight loss, with tolerability varying by trial and dose. Antifibrotic benefit and long-term durability are still preliminary, based on limited Phase 2 data. GI side effects are the main risk, and it is not yet FDA-approved.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Pemvidutide is a novel investigational peptide developed by Altimmune that functions as a balanced 1:1 glucagon/GLP-1 dual receptor agonist. Unlike GLP-1/GIP agonists (such as tirzepatide), pemvidutide combines GLP-1 activity with glucagon receptor activation in equal measure, which is believed to directly target liver fat through enhanced fatty acid oxidation while also reducing appetite and body weight. This dual mechanism makes pemvidutide particularly suited for MASH (metabolic dysfunction-associated steatohepatitis), a serious liver disease closely linked to obesity.

In the IMPACT Phase 2b trial (n=212, 48 weeks) in patients with biopsy-confirmed MASH and fibrosis stages F2/F3, pemvidutide achieved statistically significant improvements in key non-invasive markers of liver fibrosis and inflammation. The higher of the two doses tested achieved 7.5% weight loss (vs 0.2% placebo) at 48 weeks with no plateau, alongside 54.7% reduction in liver fat content, substantial reductions in ELF score (-0.58 vs +0.16 placebo) and liver stiffness (-3.97 kPa vs -0.03 placebo). The adverse event discontinuation rate was lower than placebo (1.2% vs 3.5%).

In a separate 24-week MASLD trial, one of the doses tested achieved a 75.2% relative reduction in liver fat content, with 84.6% of participants achieving 50% or greater liver fat reduction and 53.8% achieving liver fat normalization. Altimmune has completed a productive End-of-Phase 2 meeting with the FDA and has initiated PERFORMA, its registrational Phase 3 MASH trial.

How it works in the body

A balanced 1:1 dual GLP-1/glucagon receptor agonist. The GLP-1 component reduces appetite and improves insulin sensitivity, while the glucagon component activates hepatic lipid oxidation and thermogenesis. This balanced ratio specifically targets liver fat accumulation (MASH/NAFLD) in addition to weight loss.

Research overview

Pemvidutide is being developed by Altimmune (Nasdaq: ALT) as a once-weekly subcutaneous injection. The clinical program has focused on two key areas: MASH/liver disease and obesity. The IMPACT Phase 2b trial (NCT05989711) was a randomized, placebo-controlled, double-blind study enrolling 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3, randomized 1:2:2 to 1.2 mg, 1.8 mg, or placebo for 48 weeks. At 24 weeks, MASH resolution improved significantly; biopsy fibrosis improvement did not. At 48 weeks, statistically significant improvements were seen in ELF, LSM, liver fat, ALT, and cT1 vs placebo. The MASLD extension study (Browne et al., JHEP Reports 2025) enrolled 64 participants with MASLD in a 24-week RCT at 1.2, 1.8, and 2.4 mg, showing liver fat reductions of 56.3-76.4% vs 14.0% placebo, with 6.2% body weight loss at 1.8 mg. Earlier Phase 2 obesity data showed pemvidutide achieved weight loss in adults with overweight/obesity. The Lancet published a commentary on pemvidutide's dual mechanism in MASH (2025). Altimmune has completed an End-of-Phase 2 meeting with FDA and has initiated PERFORMA Phase 3 for MASH; FDA was open to incorporating AIM-MASH AI Assist for histologic assessment standardization.

Who researches Pemvidutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • Those with History of pancreatitis

    High

    GLP-1 class effect on pancreatitis risk.

  • Those with Severe gastroparesis

    High

    GLP-1 component slows gastric emptying.

  • Those who are pregnant or breastfeeding

    Absolute

    Investigational — no reproductive safety data.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • History of pancreatitis

    High

    GLP-1 class effect on pancreatitis risk.

  • Severe gastroparesis

    High

    GLP-1 component slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Investigational — no reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Gastrointestinal adverse events (GLP-1 class effect)

    High

    PMID 41113119 / PMC12529369; PMID 41237796

  • Glucagon-mediated effects on blood glucose

    Low

    PMID 41113119 / PMC12529369; PMID 41237796

  • Limited Phase 3 data

    High

    ClinicalTrials.gov: NCT05989711, NCT06987513, NCT07009860

Interaction summary(8)

Rated by direction with this peptide

  • Insulin and sulfonylureas

    CautionModerate

    GLP-1 receptor agonism plus weight loss lowers insulin requirements, so co-administered insulin or secretagogues can precipitate hypoglycemia and generally need proactive dose reduction — a well-established class effect, though not specifically characterized for pemvidutide.

    GLP-1 RA class labeling (FDA); PMID 41113119

  • Orally administered drugs generally (delayed gastric emptying)

    CautionLow

    GLP-1 agonists slow gastric emptying and can alter oral drug absorption rate; a dedicated phase 1 DDI study of pemvidutide with metformin, warfarin, atorvastatin, digoxin and a combined oral contraceptive was conducted specifically to size this effect (interventions verified on the registry).

    ClinicalTrials.gov NCT04972396

  • Warfarin

    CautionLow

    Narrow-therapeutic-index anticoagulant whose PK was formally evaluated alongside pemvidutide in the phase 1 DDI study; INR monitoring is prudent when starting or escalating, though no clinically significant interaction has been reported.

    ClinicalTrials.gov NCT04972396

  • Combined oral contraceptives

    CautionTheoretical

    Ethinylestradiol/levonorgestrel exposure was assessed in the pemvidutide DDI study because delayed gastric emptying and GI adverse events (vomiting) could theoretically reduce contraceptive absorption; no efficacy failure has been demonstrated.

    ClinicalTrials.gov NCT04972396

  • Other GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)

    CautionModerate

    Concurrent use duplicates GLP-1 receptor agonism with no added benefit and additive GI toxicity and hypoglycemia risk; incretin agents are not co-prescribed as a class rule.

    GLP-1 RA class labeling (FDA)

  • Alcohol

    CautionLow

    Alcohol independently drives steatohepatitis and would confound the hepatic benefit; pemvidutide is itself being studied in alcohol use disorder (RECLAIM) and alcohol-associated liver disease (RESTORE), so its interaction with alcohol is an open research question rather than a settled or characterized safety finding — severity kept Low to reflect that no human interaction data exist.

    ClinicalTrials.gov NCT06987513, NCT07009860

  • Resmetirom (THR-beta agonist)

    SynergisticTheoretical

    Mechanistically complementary for MASH — hepatic thyroid-hormone-receptor-beta lipid oxidation versus systemic GLP-1/glucagon action — but no combination trial has been run and the synergy is entirely inferred.

    Mechanism-only; no combination trial registered

  • Antihypertensives

    CautionLow

    Pemvidutide lowered blood pressure alongside weight in pooled/meta-analysis data, so additive hypotension is plausible in patients on existing antihypertensive regimens.

    PMID 41879841 (GRADE meta-analysis reporting blood pressure reduction)

Known risks(3)

  • Gastrointestinal adverse events (GLP-1 class effect)

    Mild

    Standard GLP-1 class GI effects (nausea, diarrhea) are expected but were notably mild in IMPACT. Discontinuation rates for AEs were lower than placebo.

  • Glucagon-mediated effects on blood glucose

    Mild / Requires Monitoring

    Glucagon receptor activation can raise blood glucose. Pemvidutide's balanced 1:1 ratio is designed to avoid this, and clinical data showed improvements in metabolic parameters, but monitoring is appropriate especially in diabetic patients.

  • Limited Phase 3 data

    PERFORMA Phase 3 is underway; confirmatory results remain pending. Larger, longer studies may reveal additional safety signals.

Drug interactions(3)

  • Insulin and insulin secretagogues

    The GLP-1 component enhances insulin secretion; co-administration with insulin or sulfonylureas may increase hypoglycemia risk. The glucagon component may partially offset this.

  • Other GLP-1 or incretin-based therapies

    Co-administration not recommended due to overlapping GLP-1 mechanisms. Additive GI effects and appetite suppression possible.

  • Oral medications with narrow therapeutic index (warfarin, levothyroxine)

    GLP-1-mediated gastric emptying delay may alter absorption of co-administered oral drugs.

Research & benefits

Evidence base

Evidence Level
Moderate-Strong Evidence
Total Studies
8

Pemvidutide has Phase 2b data in MASH (n=212, 48 weeks) and Phase 2 data in MASLD (n=64, 24 weeks), both demonstrating significant efficacy on liver endpoints and weight loss. FDA End-of-Phase 2 meeting completed with alignment on Phase 3 design. The PERFORMA Phase 3 registrational trial is underway.

Researched for(6)

Rated by confidence in the evidence

  • Improved non-invasive fibrosis markers in MASH; biopsy-confirmed antifibrotic benefit remains unproven.

    Low

    Biopsy fibrosis endpoint was negative, leaving only surrogate marker evidence, still preliminary.

    PMID 41237796 (Noureddin et al., Lancet 2025, IMPACT 24-wk); PMID 41879841 (GRADE meta-analysis, ELF MD -0.44); NCT05989711

  • Dramatic liver fat reduction (54.7% at 1.8 mg in MASH; 75.2% in MASLD at 24 weeks)

    High

    Confirmed in a randomized 24-week trial, with up to 75% relative liver fat reduction vs placebo.

    PMID 41113119 / PMC12529369 (Browne et al., JHEP Rep 2025, NCT05292911); PMID 39002641 (Harrison et al., J Hepatol)

  • Clinically meaningful weight loss (up to 7.5% vs 0.2% placebo at 48 weeks in MASH)

    High

    Human RCT data show significant body weight reduction, up to 6.2% at 24 weeks vs placebo.

    PMID 41113119 / PMC12529369; NCT04561245; NCT05989711

  • Outstanding tolerability — lower discontinuation rate than placebo (1.2% vs 3.5%)

    Medium

    Discontinuation due to adverse events was low in IMPACT but higher than placebo in the higher-dose MOMENTUM groups.

    PMID 41237796 (Lancet, IMPACT); PMID 41113119 / PMC12529369 (JHEP Rep)

  • No weight loss plateau observed at 48 weeks with 1.8 mg dose

    Speculative

    Single unpublished trial readout suggests continued weight loss at 48 weeks without plateau.

    NCT05989711 (48-wk results not published at time of check)

  • Liver fat normalization in majority of MASLD patients (53.8% achieved <=5% liver fat at 1.8 mg)

    High

    Randomized trial found over half of patients reached normal liver fat levels at 1.8 mg.

    PMID 41113119 / PMC12529369 (Browne et al., JHEP Rep 2025, NCT05292911)

Benefits(6)

  • Improved non-invasive fibrosis markers in MASH; biopsy-confirmed antifibrotic benefit remains unproven.

    IMPACT Phase 2b (NCT05989711, n=212, 48 weeks, Altimmune Dec 2025)

  • Dramatic liver fat reduction (54.7% at 1.8 mg in MASH; 75.2% in MASLD at 24 weeks)

    IMPACT Phase 2b and MASLD trial (Browne et al., JHEP Reports 2025)

  • Clinically meaningful weight loss (up to 7.5% vs 0.2% placebo at 48 weeks in MASH)

    IMPACT Phase 2b at 48 weeks

  • Outstanding tolerability — lower discontinuation rate than placebo (1.2% vs 3.5%)

    IMPACT Phase 2b — no serious or severe treatment-related AEs

  • No weight loss plateau observed at 48 weeks with 1.8 mg dose

    IMPACT Phase 2b — continued weight loss from 24 to 48 weeks

  • Liver fat normalization in majority of MASLD patients (53.8% achieved <=5% liver fat at 1.8 mg)

    MASLD trial (Browne et al., JHEP Reports 2025, n=64)

Key studies(2)

  1. Altimmune / Noureddin M (PI)

    Altimmune press release (December 2025); The Lancet commentary (2025)

    2025

    Pemvidutide 1.8 mg achieved ELF -0.58 vs +0.16 placebo, LSM -3.97 vs -0.03 placebo, liver fat -54.7% vs -8.2%, ALT -37.4 vs -10.3 IU/L, and 7.5% weight loss vs 0.2% placebo. 32.4% achieved combined ELF and LSM targets vs 3.2% placebo. Discontinuation due to AEs 1.2% vs 3.5% placebo. These were secondary non-invasive measures at 48 weeks; LSM comparisons had p<0.05 and p<0.001. The biopsy fibrosis primary endpoint was not met at 24 weeks.

  2. Browne SK, Suschak JJ, Tomah S, Gutierrez JA, et al.

    JHEP Reports

    2025

    Pemvidutide 1.8 mg achieved 75.2% relative liver fat reduction vs 14% placebo (p<0.001). 84.6% achieved >=50% liver fat reduction; 53.8% achieved normalization (<=5% liver fat). Body weight reduced 6.2% (p<0.001 vs placebo). Well tolerated at all doses.

Regulation & availability

Why researchers look at it

Pemvidutide sits at the intersection of obesity and liver disease. Its balanced GLP-1/glucagon mechanism targets liver fat — achieving 75% liver fat reduction in some trials — while also delivering meaningful weight loss, with low discontinuation in IMPACT; tolerability varied across trials.

Estimated cost
No approved product or established prescription price; Phase 3 underway.
FDA status
Not FDA-approved; pemvidutide is an investigational drug available in the US only through clinical trials, and it is not eligible for compounding. PERFORMA Phase 3 is underway following FDA End-of-Phase 2 feedback on MASH trial design; Altimmune announced its initiation on August 3, 2026. FDA was open to incorporating AIM-MASH AI Assist for histological assessment.
WADA status
Prohibited at all times under WADA S0 because pemvidutide has no governmental approval for human therapeutic use. It need not be explicitly named.
Prescribability
Pemvidutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. No — investigational; PERFORMA Phase 3 underway.
Availability
Pemvidutide is an investigational drug with no approved prescription product. It has completed Phase 2b trials for MASH, and PERFORMA Phase 3 is underway, with 52-week results anticipated in 2029. Approval timing is unconfirmed.

International status

  • US

    Pemvidutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding.

  • Worldwide

    Investigational — not yet approved anywhere

Regulatory timeline(9)

  1. 2021
    Pemvidutide enters Phase 1 clinical development at Altimmune
  2. 2022
    Phase 2 obesity trial initiated
  3. 2023
    Phase 2 MASLD trial results — significant liver fat reductions
  4. 2024
    IMPACT Phase 2b trial (MASH, F2/F3) initiated (NCT05989711, n=212)
  5. 2025-H1
    IMPACT met the MASH-resolution endpoint but missed the fibrosis-improvement endpoint.
  6. 2025-11
    MASLD 24-week extension results published in JHEP Reports
  7. 2025-12
    IMPACT 48-week topline results — significant improvements in all endpoints vs placebo
  8. 2025-12
    End-of-Phase 2 meeting with FDA — alignment on Phase 3 design for MASH F2/F3
  9. 2026-08-03
    Altimmune announced initiation of PERFORMA, its registrational Phase 3 MASH trial.

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

What makes pemvidutide different from semaglutide or tirzepatide?

Pemvidutide is a balanced 1:1 GLP-1/glucagon dual agonist, meaning it activates both the GLP-1 and glucagon receptors equally. The glucagon component directly targets the liver, promoting fatty acid oxidation and inhibiting lipogenesis. This gives pemvidutide a strong advantage for liver disease (MASH/MASLD) compared to GLP-1-only drugs.

Is pemvidutide being developed for obesity or liver disease?

Primarily for MASH (liver disease) based on the Phase 2b IMPACT trial. However, it also produces meaningful weight loss (7.5% in MASH patients at 48 weeks). The Phase 3 program will focus on MASH with advanced fibrosis as the initial indication.

How is pemvidutide administered?

Pemvidutide is a subcutaneous injection, similar to semaglutide (Ozempic/Wegovy).

How well tolerated is pemvidutide?

Extremely well tolerated. In the IMPACT Phase 2b trial, the discontinuation rate due to adverse events was actually lower for pemvidutide (0-1.2%) than for placebo (3.5%). No serious or severe treatment-related AEs were reported.